Global analysis of p53-regulated transcription identifies its direct targets and unexpected regulatory mechanisms

eLife

Volumn 2014, Issue 3, 2014, Pages

  Allen, Mary Ann ^a,b,c   Andrysik, Zdenek ^a,b   Dengler, Veronica L ^a,b   Mellert, Hestia S ^a,b   Guarnieri, Anna ^a,b   Freeman, Justin A ^a,b   Sullivan, Kelly D ^a,b   Galbraith, Matthew D ^a,b   Luo, Xin ^d   Lee Kraus, W ^d   Dowell, Robin D ^a,b   Espinosa, Joaquin M ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN G1; GROWTH DIFFERENTIATION FACTOR 15; MICRORNA 34A; NUTLIN 3; PROTEIN MDM2; PROTEIN P53;

APOPTOSIS; ARTICLE; CELL CULTURE; CHROMATIN IMMUNOPRECIPITATION; COMPARATIVE STUDY; CONTROLLED STUDY; DOWN REGULATION; FLOW CYTOMETRY; GENE; GENE MAPPING; GENE OVEREXPRESSION; GENE SEQUENCE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; PTP4A1 GENE; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; RNA SYNTHESIS; STEADY STATE; TRANSCRIPTION REGULATION; WESTERN BLOTTING;

EID: 84902324667     PISSN: None     EISSN: 2050084X     Source Type: Journal    
DOI: 10.7554/eLife.02200.001     Document Type: Article

References (52)

1. Anders S, Huber W. 2010. Differential expression analysis for sequence count data. Genome Biology 11:R106. doi: 10.1186/gb-2010-11-10-r106.
2. Andrysik A, Kim J, Tan AC, Espinosa JM. 2013. A genetic screen identifies TCF3/E2A and TRIAP1 as pathway-specific regulators of the cellular response to p53 activation. Cell Reports 3:1-9. doi: 10.1016/j.celrep.2013.04.014.
3. Benson EK, Mungamuri SK, Attie O, Kracikova M, Sachidanandam R, Manfredi JJ, Aaronson SA. 2013. p53-dependent gene repression through p21 is mediated by recruitment of E2F4 repression complexes. Oncogene doi: 10.1038/onc.2013.378.
4. Biderman L, Manley JL, Prives C. 2012. Mdm2 and MdmX as regulators of gene expression. Genes & cancer 3:264-273. doi: 10.1177/1947601912455331.
5. Brown CJ, Lain S, Verma CS, Fersht AR, Lane DP. 2009. Awakening guardian angels: drugging the p53 pathway. Nature Reviews Cancer 9:862-873. doi: 10.1038/nrc2763.
6. Chen X, Ko LJ, Jayaraman L, Prives C. 1996. p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. Genes & Development 10:2438-2451. doi: 10.1101/gad.10.19.2438.
7. Cohen PA, Mani JC, Lane DP. 1998. Characterization of a new intrabody directed against the N-terminal region of human p53. Oncogene 17:2445-2456. doi: 10.1038/sj.onc.1202190.
8. Core LJ, Waterfall JJ, Lis JT. 2008. Nascent RNA sequencing reveals widespread pausing and divergent initiation at human promoters. Science 322:1845-1848. doi: 10.1126/science.1162228.
9. Das S, Raj L, Zhao B, Kimura Y, Bernstein A, Aaronson SA, Lee SW. 2007. Hzf Determines cell survival upon genotoxic stress by modulating p53 transactivation. Cell 130:624-637. doi: 10.1016/j.cell.2007.06.013.
10. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B. 1993. WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825. doi: 10.1016/0092-8674(93)90500-P.
11. Espinosa JM, Emerson BM. 2001. Transcriptional regulation by p53 through intrinsic DNA/chromatin binding and site-directed cofactor recruitment. Molecular Cell 8:57-69. doi: 10.1016/S1097-2765(01)00283-0.
12. Espinosa JM, Verdun RE, Emerson BM. 2003. p53 functions through stress-and promoter-specific recruitment of transcription initiation components before and after DNA damage. Molecular Cell 12:1015-1027. doi: 10.1016/S1097-2765(03)00359-9.
13. Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW, Greninger P, Thompson IR, Luo X, Soares J, Liu Q, Iorio F, Surdez D, Chen L, Milano RJ, Bignell GR, Tam AT, Davies H, Stevenson JA, Barthorpe S, Lutz SR, Kogera F, Lawrence K, McLaren-Douglas A, Mitropoulos X, Mironenko T, Thi H, Richardson L, Zhou W, Jewitt F, Zhang T, O'Brien P, Boisvert JL, Price S, Hur W, Yang W, Deng X, Butler A, Choi HG, Chang JW, Baselga J, Stamenkovic I, Engelman JA, Sharma SV, Delattre O, Saez-Rodriguez J, Gray NS, Settleman J, Futreal PA, Haber DA, Stratton MR, Ramaswamy S, McDermott U, Benes CH. 2012. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483:570-575. doi: 10.1038/nature11005.
14. Gomes NP, Bjerke G, Llorente B, Szostek SA, Emerson BM, Espinosa JM. 2006. Gene-specific requirement for P-TEFb activity and RNA polymerase II phosphorylation within the p53 transcriptional program. Genes & Development 20:601-612. doi: 10.1101/gad.1398206.
15. Hah N, Danko CG, Core L, Waterfall JJ, Siepel A, Lis JT, Kraus WL. 2011. A rapid, extensive, and transient transcriptional response to estrogen signaling in breast cancer cells. Cell 145:622-634. doi: 10.1016/j.cell.2011.03.042.
16. Hargreaves DC, Horng T, Medzhitov R. 2009. Control of inducible gene expression by signal-dependent transcriptional elongation. Cell 138:129-145. doi: 10.1016/j.cell.2009.05.047.
17. Henry RE, Andrysik Z, Paris R, Galbraith MD, Espinosa JM. 2012. A DR4:tBID axis drives the p53 apoptotic response by promoting oligomerization of poised BAX. The EMBO Journal 31:1266-1278. doi: 10.1038/emboj.2011.498.
18. Ivshina AV, George J, Senko O, Mow B, Putti TC, Smeds J, Lindahl T, Pawitan Y, Hall P, Nordgren H, Wong JE, Liu ET, Bergh J, Kuznetsov VA, Miller LD. 2006. Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Research 66:10292-10301. doi: 10.1158/0008-5472.CAN-05-4414.
19. Jiao AL, Slack FJ. 2013. RNA-mediated gene activation. Epigenetics 9:27-36. doi: 10.4161/epi.26942.
20. Jin F, Li Y, Dixon JR, Selvaraj S, Ye Z, Lee AY, Yen CA, Schmitt AD, Espinoza CA, Ren B. 2013. A high-resolution map of the three-dimensional chromatin interactome in human cells. Nature 503:290-294. doi: 10.1038/nature12644.
21. Kubbutat MH, Jones SN, Vousden KH. 1997. Regulation of p53 stability by Mdm2. Nature 387:299-303. doi: 10.1038/387299a0.
22. Lal A, Thomas MP, Altschuler G, Navarro F, O'Day E, Li XL, Concepcion C, Han YC, Thiery J, Rajani DK, Deutsch A, Hofmann O, Ventura A, Hide W, Lieberman J. 2011. Capture of microRNA-bound mRNAs identifies the tumor suppressor miR-34a as a regulator of growth factor signaling. PLOS Genetics 7:e1002363. doi: 10.1371/journal.pgen.1002363.
23. Laptenko O, Prives C. 2006. Transcriptional regulation by p53: one protein, many possibilities. Cell Death and Differentiation 13:951-961. doi: 10.1038/sj.cdd.4401916.
24. Li M, He Y, Dubois W, Wu X, Shi J, Huang J. 2012. Distinct regulatory mechanisms and functions for p53-activated and p53-repressed DNA damage response genes in embryonic stem cells. Molecular Cell 46:30-42. doi: 10.1016/j.molcel.2012.01.020.
25. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T. 1994. p53 status and the efficacy of cancer therapy in vivo. Science 266:807-810. doi: 10.1126/science.7973635.
26. Melo CA, Drost J, Wijchers PJ, van de Werken H, de Wit E, Oude Vrielink JA, Elkon R, Melo SA, Leveille N, Kalluri R, de Laat W, Agami R. 2013. eRNAs are required for p53-dependent enhancer activity and gene transcription. Molecular Cell 49:524-535. doi: 10.1016/j.molcel.2012.11.021.
27. Menendez D, Nguyen TA, Freudenberg JM, Mathew VJ, Anderson CW, Jothi R, Resnick MA. 2013. Diverse stresses dramatically alter genome-wide p53 binding and transactivation landscape in human cancer cells. Nucleic Acids Research 41:7286-7301. doi: 10.1093/nar/gkt504.
28. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. 1992. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69:1237-1245. doi: 10.1016/0092-8674(92)90644-R.
29. Morachis JM, Murawsky CM, Emerson BM. 2010. Regulation of the p53 transcriptional response by structurally diverse core promoters. Genes & Development 24:135-147. doi: 10.1101/gad.1856710.
30. Nikulenkov F, Spinnler C, Li H, Tonelli C, Shi Y, Turunen M, Kivioja T, Ignatiev I, Kel A, Taipale J, Selivanova G. 2012. Insights into p53 transcriptional function via genome-wide chromatin occupancy and gene expression analysis. Cell Death and Differentiation 19:1992-2002. doi: 10.1038/cdd.2012.89.
31. Ohkubo S, Tanaka T, Taya Y, Kitazato K, Prives C. 2006. Excess HDM2 impacts cell cycle and apoptosis and has a selective effect on p53-dependent transcription. The Journal of Biological Chemistry 281:16943-16950. doi: 10.1074/jbc.M601388200.
32. Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B. 1993. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 362:857-860. doi: 10.1038/362857a0.
33. Picksley SM, Vojtesek B, Sparks A, Lane DP. 1994. Immunochemical analysis of the interaction of p53 with MDM2;-fine mapping of the MDM2 binding site on p53 using synthetic peptides. Oncogene 9:2523-2529.
34. Polyak K, Xia Y, Zweier JL, Kinzler KW, Vogelstein B. 1997. A model for p53-induced apoptosis. Nature 389:300-305. doi: 10.1038/38525.
35. Poyurovsky MV, Katz C, Laptenko O, Beckerman R, Lokshin M, Ahn J, Byeon IJ, Gabizon R, Mattia M, Zupnick A, Brown LM, Friedler A, Prives C. 2010. The C terminus of p53 binds the N-terminal domain of MDM2. Nature Structural & Molecular Biology 17:982-989. doi: 10.1038/nsmb.1872.
36. Riemenschneider MJ, Buschges R, Wolter M, Reifenberger J, Bostrom J, Kraus JA, Schlegel U, Reifenberger G. 1999. Amplification and overexpression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification. Cancer Research 59:6091-6096.
37. Riley T, Sontag E, Chen P, Levine A. 2008. Transcriptional control of human p53-regulated genes. Nature Reviews Molecular Cell Biology 9:402-412. doi: 10.1038/nrm2395.
38. Schlereth K, Heyl C, Krampitz AM, Mernberger M, Finkernagel F, Scharfe M, Jarek M, Leich E, Rosenwald A, Stiewe T. 2013. Characterization of the p53 cistrome-DNA binding cooperativity dissects p53's tumor suppressor functions. PLOS Genetics 9:e1003726. doi: 10.1371/journal.pgen.1003726.
39. Smeenk L, van Heeringen SJ, Koeppel M, van Driel MA, Bartels SJ, Akkers RC, Denissov S, Stunnenberg HG, Lohrum M. 2008. Characterization of genome-wide p53-binding sites upon stress response. Nucleic Acids Research 36:3639-3654. doi: 10.1093/nar/gkn232.
40. Smeenk L, van Heeringen SJ, Koeppel M, Gilbert B, Janssen-Megens E, Stunnenberg HG, Lohrum M. 2011. Role of p53 serine 46 in p53 target gene regulation. PLOS ONE 6:e17574. doi: 10.1371/journal.pone.0017574.
41. Sullivan KD, Padilla-Just N, Henry RE, Porter CC, Kim J, Tentler JJ, Eckhardt SG, Tan AC, DeGregori J, Espinosa JM. 2012. ATM and MET kinases are synthetic lethal with nongenotoxic activation of p53. Nature Chemical Biology 8:646-654. doi: 10.1038/nchembio.965.
42. Szak ST, Mays D, Pietenpol JA. 2001. Kinetics of p53 binding to promoter sites in vivo. Molecular and Cellular Biology 21:3375-3386. doi: 10.1128/MCB.21.10.3375-3386.2001.
43. Tang HY, Zhao K, Pizzolato JF, Fonarev M, Langer JC, Manfredi JJ. 1998. Constitutive expression of the cyclin-dependent kinase inhibitor p21 is transcriptionally regulated by the tumor suppressor protein p53. The Journal of Biological Chemistry 273:29156-29163. doi: 10.1074/jbc.273.44.29156.
44. Thut CJ, Goodrich JA, Tjian R. 1997. Repression of p53-mediated transcription by MDM2: a dual mechanism. Genes & Development 11:1974-1986. doi: 10.1101/gad.11.15.1974.
45. Tovar C, Rosinski J, Filipovic Z, Higgins B, Kolinsky K, Hilton H, Zhao X, Vu BT, Qing W, Packman K, Myklebost O, Heimbrook DC, Vassilev LT. 2006. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proceedings of the National Academy of Sciences of the United States of America 103:1888-1893. doi: 10.1073/pnas.0507493103.
46. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N, Liu EA. 2004. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303:844-848. doi: 10.1126/science.1092472.
47. Vousden KH, Prives C. 2009. Blinded by the light: the growing complexity of p53. Cell 137:413-431. doi: 10.1016/j.cell.2009.04.037.
48. Wang B, Niu D, Lam TH, Xiao Z, Ren EC. 2013. Mapping the p53 transcriptome universe using p53 natural polymorphs. Cell Death and Differentiation 21:521-532. doi: 10.1038/cdd.2013.132.
49. Wei CL, Wu Q, Vega VB, Chiu KP, Ng P, Zhang T, Shahab A, Yong HC, Fu Y, Weng Z, Liu J, Zhao XD, Chew JL, Lee YL, Kuznetsov VA, Sung WK, Miller LD, Lim B, Liu ET, Yu Q, Ng HH, Ruan Y. 2006. A global map of p53 transcription-factor binding sites in the human genome. Cell 124:207-219. doi: 10.1016/j.cell.2005.10.043.
50. White DE, Talbott KE, Arva NC, Bargonetti J. 2006. Mouse double minute 2 associates with chromatin in the presence of p53 and is released to facilitate activation of transcription. Cancer Research 66:3463-3470. doi: 10.1158/0008-5472.CAN-05-1381.
51. Yan J, Jiang J, Lim CA, Wu Q, Ng HH, Chin KC. 2007. BLIMP1 regulates cell growth through repression of p53 transcription. Proceedings of the National Academy of Sciences of the United States of America 104:1841-1846. doi: 10.1073/pnas.0605562104.
52. Zhao R, Gish K, Murphy M, Yin Y, Notterman D, Hoffman WH, Tom E, Mack DH, Levine AJ. 2000. Analysis of p53-regulated gene expression patterns using oligonucleotide arrays. Genes & Development 14:981-993. doi: 10.1101/gad.827700.